Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Telzir | Fosamprenavir calcium | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
Ebixa | Memantine hydrochloride | Dementia (Alzheimer type), moderate to severe | Do not list | Complete | ||
Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | ||
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Withdrawn | |||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
VFEND | Voriconazole | Aspergillosis, Invasive | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete |